Dr. Sriram Naganathan
Dr. Naganathan came to the University of Kansas in the early 1980s where he obtained a master’s degree in 1990, developing synthetic methodology under the direction of Professor Thomas Engler. He received his Ph.D. under the mentorship of Professor Eric Block at SUNY-Albany studying the chemistry of sulfur compounds in allium plants. After postdoctoral studies at the University of Pittsburgh with Professor Paul Dowd, he began his career in the pharmaceutical industry when he joined the specialty chemicals group at Pfizer in 1994 as a Senior Research Scientist. In 1997 he moved to Roche Bioscience and subsequently worked in smaller biopharmaceutical companies: CellGate, Exelixis and Dermira. Most recently, Dr. Naganathan was the Executive Director and Head of CMC at Nurix Therapeutics, where he was responsible for clinical trial materials. In February 2023, he transitioned to his current position at Revolution Medicines, Inc. where he is Vice President, Technical Operations. During his career, he has worked on several marketed drugs and food ingredients.